As the first-ever Medicare drug-price negotiations take shape, Big Pharma-backed Democrats want to limit the number of costly medicines regulators can target.
Democratic Reps. Scott Peters (Calif.), Wiley Nickel (N.C.), Josh Gottheimer (N.J.) and Donald Davis (N.C.) are each co-sponsoring at least one of several proposed bills that would limit regulators’ ability to negotiate down prices of drugs covered by the Medicare government insurance program. The legislation would erode the drug-pricing reforms included in the Democrats’ 2022 Inflation Reduction Act — efforts that Peters, Nickel, and Gottheimer supported. (Davis had not yet been elected to Congress.)
The four, who all hail from states with a major biotech or drug-industry presence, have together raked in more than $300,000 from pharmaceutical and health-products interests during the 2023-2024 congressional session. Gottheimer is reportedly eyeing a 2025 gubernatorial run in New Jersey, home to the pharmaceutical giant Merck & Co.
Recent Posts
‘The Siege Must Be Broken’: Countries Called to Ship Fuel to Cuba After Trump Tariffs Struck Down
Take Action Now The US Supreme Court’s ruling “implies that Trump’s recent order imposing tariffs on countries selling oil to Cuba exceeds the…
Elite Depravity in Imperial Decline, A Zero Hour Conversation With Richard Wolff
Take Action Now “The system self-selects for psychopathy… the most sociopathically obsessive competitor and accumulator of personal power and…
Economics of Health For All: The Plan to Put Health at the Heart of the Global Economy
Take Action Now At the World Health Assembly in May, member states may endorse an unprecedented strategy declaring that health is not a cost – but…
The Left Owes a Lot to Jesse Jackson
Take Action Now As a movement builder, spokesperson, and candidate for the presidency, Jesse Jackson’s accomplishments were massive. He was one of…